Drug Trial Radar · NCT01962207
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination
Last checked: Nov 19, 2026Latest source record: Jun 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Oct 2013
Primary completion
Dec 2017
Study completion Jun 2018
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10 years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ or Mencevax™ ACWY, and the safety and immunogenicity of a booster dose of MenACWY-TT administered 10 years after the primary vaccination. All subjects received a primary vaccination at 1 to 10 years of age in study 108658 (NCT00427908). No new subjects will be enrolled in this booster study.
Conditions
- Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612Biological
One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary VaccinationTime frame: 6 years after primary vaccination (Year 1 of study MENACWY-TT-100)
- Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary VaccinationTime frame: 7 years after primary vaccination (Year 2 of study MENACWY-TT-100)
- Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary VaccinationTime frame: 8 years after primary vaccination (Year 3 of study MENACWY-TT-100)
- Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary VaccinationTime frame: 9 years after primary vaccination (Year 4 of study MENACWY-TT-100)
- Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary VaccinationTime frame: 10 years after primary vaccination (Year 4 of study MENACWY-TT-100)
- Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary VaccinationTime frame: 6 Years after primary vaccination (Year 1 of study MENACWY-TT-100)
- Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary VaccinationTime frame: 7 years after primary vaccination (Year 2 of study MENACWY-TT-100)
- Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary VaccinationTime frame: 8 years after primary vaccination (Year 3 of study MENACWY-TT-100)
- Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary VaccinationTime frame: 9 years after primary vaccination (Year 4 of study MENACWY-TT-100)
- Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary VaccinationTime frame: 10 years after primary vaccination (Year 5 of study MENACWY-TT-100)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Espoo Vaccine Research Clinic
Espoo, Finland
South Helsinki Vaccine Research Clinic
Helsinki, Finland
Helsinki East Vaccine Research Clinic
Helsinki, Finland
Jarvenpaa Vaccine Research Clinic
Jarvenpaa, Finland
Tampereen yliopisto/ Oulun rokotetutkimusklinikka
Oulu, Finland
Tampereen yliopisto/ Porin rokotetutkimusklinikka
Pori, Finland
Tampere Vaccine Research Clinic
Tampere, Finland
Tampereen yliopisto/ Turun rokotetutkimusklinikka
Turku, Finland
Tampereen yliopisto/ Ita-Vantaan rokotetutkimusklinikka
Vantaa, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.